Company Overview

Sanofi is a global biopharmaceutical company focused on the research, development, manufacturing, and commercialization of medicines and vaccines across multiple therapeutic areas. The company operates primarily within the pharmaceuticals and vaccines industries, with a strategic emphasis on innovative specialty care, immunology, oncology, rare diseases, and preventive healthcare. Its core revenue drivers include prescription medicines, specialty biologics, and vaccines sold to governments, healthcare systems, and private providers.

Founded in 1973 through the merger of several French pharmaceutical entities and later expanded through major acquisitions, Sanofi evolved into a global healthcare leader. A pivotal milestone was the 2004 merger with Aventis, which significantly expanded its R&D capabilities and international footprint. In recent years, Sanofi has repositioned itself toward science-driven innovation, streamlining legacy businesses while increasing investment in biologics and immunology to strengthen long-term growth.

Business Operations

Sanofi organizes its operations around several major business segments, primarily Specialty Care, Vaccines, General Medicines, and Consumer Healthcare. Specialty Care focuses on immunology, rare diseases, neurology, and oncology, with biologic therapies such as Dupixent representing a substantial portion of revenue. The Vaccines segment, operated through Sanofi Pasteur, develops and supplies vaccines for infectious diseases, including influenza and pediatric vaccines, serving both public and private markets worldwide.

The company maintains extensive global manufacturing and R&D infrastructure, with facilities across North America, Europe, Asia, and emerging markets. Sanofi controls a broad portfolio of proprietary technologies in biologics, monoclonal antibodies, and vaccine platforms. It operates through numerous subsidiaries, including Sanofi Pasteur, Genzyme, and Opella (consumer healthcare), and engages in strategic collaborations with biotechnology firms and academic institutions to advance its research pipeline.

Strategic Position & Investments

Sanofi’s strategy centers on becoming a pure-play, innovation-driven biopharma company, prioritizing high-growth therapeutic areas while reducing exposure to lower-margin legacy products. Growth initiatives include expanding its immunology and specialty care pipeline, advancing first- and best-in-class biologic therapies, and increasing R&D productivity through platform-based research and digital integration.

The company has pursued targeted acquisitions and divestments to support this strategy, including the acquisition of Principia Biopharma to strengthen its immunology portfolio and the planned separation of Opella to sharpen focus on prescription medicines and vaccines. Sanofi is also investing in emerging technologies such as mRNA research, next-generation antibody platforms, and AI-enabled drug discovery to enhance long-term innovation and competitive positioning.

Geographic Footprint

Sanofi is headquartered in Europe (France) and operates in more than 100 countries worldwide. Its largest markets include North America, Western Europe, and Asia-Pacific, with the United States representing a significant share of revenue due to strong specialty care and vaccine sales. The company also maintains a substantial presence in Latin America, Africa, and the Middle East, supporting both commercial sales and public health initiatives.

Manufacturing, R&D, and commercial operations are distributed globally, enabling Sanofi to serve diverse healthcare systems and regulatory environments. The company plays a significant role in international vaccine supply, partnering with governments and global health organizations to support immunization programs and pandemic preparedness.

Leadership & Governance

Sanofi is led by an executive team with a stated focus on science-driven growth, disciplined capital allocation, and long-term value creation. The leadership emphasizes simplifying the organizational structure, accelerating innovation, and fostering a culture of accountability and patient-centric decision-making.

Key executives include:

• Paul Hudson – Chief Executive Officer
• Jean-François Dehecq – Chairman of the Board
• Franck Riester – Chief Financial Officer
• Houman Ashrafian – Head of Research and Development
• Thomas Kudela – Global Head of Manufacturing and Supply

The board and executive leadership oversee governance in alignment with international regulatory standards and public company requirements, with strategic oversight informed by long-term scientific and financial objectives.